top of page
Search

Randomized Control Trial: EmoLED

  • Writer: Kerr Biotech
    Kerr Biotech
  • May 5
  • 2 min read

Fresh off the press, a new publication reports on the effect of photobiomodulation using blue light (EmoLED) in the treatment of stage 2 and stage 3 pressure ulcers: The RISE_UP study https://doi.org/10.1016/j.jtv.2025.100895


Abstract

  • The study assesses blue light photobiomodulation's effectiveness in healing stage 2 and 3 pressure ulcers. ​

  • Results indicate that blue light therapy promotes tissue repair and stabilizes wounds that may worsen with standard care. ​

  • The trial shows a significant difference in healing rates between the treatment and control groups, improving patients' quality of life. ​

EmoLED treating PI

Introduction

  • Pressure ulcers (PUs) are a significant public health issue, affecting 12% of hospitalized patients. ​

  • They result from pressure-induced damage to the skin, leading to hypoxia and necrosis. ​

  • Patients with limited mobility, such as the elderly and those with spinal cord injuries, are at higher risk. ​


Materials and Methods

  • The R.I.S.E._U.P. study was a randomized controlled trial conducted in Italy

  • 40 patients with stage 2 and 3 pressure ulcers were enrolled, receiving either standard care or blue light therapy (EmoLED). ​applied thrice weekly for four weeks. ​


Results

  • The treatment group showed a mean PUSH score reduction of 3.29, compared to 2.29 in the control group. ​

  • 97.2% of EmoLED treated patients were classified as responders, compared to 56.1% in the control group.

  • Image analysis indicated a mean wound area reduction of 52.46% in the treatment group versus 29.83% in the control group. ​

doi:10.4081/ijwc.2023.97
doi:10.4081/ijwc.2023.97

Discussion

  • Blue light therapy effectively accelerates wound healing and re-epithelialization in chronic wounds. ​

  • The study is the first to evaluate blue light photobiomodulation specifically for pressure ulcers. ​

  • Limitations include a small sample size and a short observation period of four weeks. ​


Conclusion

  • Blue light therapy is a valuable addition to standard care for chronic pressure ulcers, promoting faster healing and improving patient quality of life. ​


These findings provide new hope for the thousands of patients afflicted by non-healing pressure injuries using a treatment modality such as EmoLED, that is non-invasive, painless, and a simple addition to standard care protocols.


Reach out to learn more about how EmoLED can enhance your patients' outcomes




 
 
 

Comments

bottom of page